KLRG1 and neoplasm: The combination of αCTLA-4 and α4-1BB demonstrated significantly higher therapeutic efficacy than α4-1BB alone (Figure 1); however, both groups show equally high increases in the frequency of tumor-infiltrating KLRG1+ T-cells in response to therapy (Figure 5A&B).